NH TherAguix develops AGuIX®, a nanodrug designed to enhance the efficacy of radiotherapy in cancer treatment by targeting tumors through specific bio-distribution mechanisms. This technology aims to improve outcomes for patients with unmet medical needs in oncology, particularly those undergoing radiotherapy.
Funding
$51.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Radiotherapy, a common cancer treatment, can lack precision, affecting healthy tissues surrounding tumors and limiting its effectiveness, especially for patients with tumors that are difficult to target or resistant to radiation. This can lead to suboptimal outcomes and increased side effects.
Solution
NH TherAguix is developing AGuIX®, a nanodrug designed to enhance the precision and efficacy of radiotherapy. AGuIX® nanoparticles are designed to selectively accumulate within tumors, acting as a contrast agent to improve tumor visualization during imaging and as a radiosensitizer to amplify the effects of radiation specifically within the tumor microenvironment. This targeted approach aims to minimize damage to healthy tissues, allowing for higher radiation doses to be delivered to the tumor, potentially improving treatment outcomes and reducing side effects for cancer patients. The company's technology has pan-cancer potential.
Target Audience
The primary target audience includes oncology professionals, radiation oncologists, and hospitals seeking to improve the precision and effectiveness of radiotherapy for cancer patients with solid tumors.
Features
- Nanoparticles designed for enhanced tumor accumulation through specific bio-distribution mechanisms.
- Acts as a radiosensitizer, increasing the sensitivity of tumor cells to radiation.
- Functions as an MRI contrast agent for improved tumor imaging and treatment planning.
- Potential to improve outcomes in a variety of solid tumors.
- Currently in multiple clinical trials.